[News] Ultra V, 2023 k-beauty trend ‘Ultra Call’ attracts great intere…
페이지 정보
작성자 ultrav 작성일23-03-08 11:32 조회1,713회관련링크
본문
[Discovery News = Reporter Myung-soo Lee] Bio-medical beauty group UltraV (CEO Han-Jin Kwon) had time to share the latest beauty know-how at the IFAAS Vancouver conference held in Vancouver, Canada on the 4th and 5th.
On this day, the world's first certified PDO MICROSPHERE biostimulator 'ULTRACOL' with its own technology was introduced, along with an overall introduction of treatment techniques and clinical know-how. After the lecture, there was a time to help the participants understand, in-depth discussions and information sharing.
'ULTRACOL' is a microsphere made of FDA-registered material PDO (POLYDIOXANONE) ingredient that stimulates self-collagen production to improve volume and lifting elasticity, and its efficacy, biodegradability and stability in the human body have been proven. It won the IR52 Jang Young-sil Award for the first time as a polymer filler, and obtained approval from the Korean Food and Drug Administration (KFDA) and European CE certification by proving its biodegradability and stability in the human body.
In particular, 'ULTRACOL' has been awarded the '5 Million Dollar Export Tower' for its differentiated technology and steadily increasing exports. It is contributing to the development of the K-beauty market by winning the Korea Excellent Patent Award with its unique patented technology.
Han-Jin Kwon, CEO and K-beauty leader, said, “Through this conference, we once again confirmed the high interest of global medical staff in ‘ULTRACOL’. We will accelerate our market penetration through this,” he emphasized.
On the other hand, Ultra V focused on securing a sustainable growth engine even in an atmosphere that was stagnant due to the COVID19 blockade. Amid the interest of medical staff around the world, we have strengthened our position and network in the global market by informing the excellence and product power of 'ULTRACOL' and continuously secured global competitiveness.